NASDAQ: COCP - Cocrystal Pharma, Inc.

Yield per half year: -15.91%
Dividend yield: 0.00%
Sector: Healthcare

Share chart Cocrystal Pharma, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About Cocrystal Pharma, Inc.

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection.

more details
It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2011-05-19
ISIN US19188J3005
Industry Pharmaceuticals
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.cocrystalpharma.com
Цена ао 1.5
Change price per day: +3.5% (1.43)
Change price per week: -5.13% (1.56)
Change price per month: -14.94% (1.74)
Change price per 3 month: -52.1% (3.09)
Change price per half year: -15.91% (1.76)
Change price per year: +5.71% (1.4)
Change price per 3 year: +150.85% (0.59)
Change price per 5 year: +8.03% (1.37)
Change price per year to date: -41.27% (2.52)
All parameters

Underestimation

Title Value Grade
P/S 0 0
P/BV 0.6694 10
P/E 0 0
EV/EBITDA 0.3066 10
Total: 5

Efficiency

Title Value Grade
ROA, % -57.53 0
ROE, % -68.16 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.0822 10
Total: 9.6

Growth impulse

Title Value Grade
Yield Revenue, % 59900 10
Yield Ebitda, % 780.55 10
Yield EPS, % -89.73 0
Total: 6
More

Institutions Volume Share, %
Vanguard Group Inc 275656 2.71
Renaissance Technologies, LLC 125128 1.23
Blackrock Inc. 74063 0.73
Geode Capital Management, LLC 60432 0.59
Morgan Stanley 59277 0.58
Susquehanna International Group, LLP 34544 0.34
State Street Corporation 24443 0.24
Northern Trust Corporation 12207 0.12
Bank of America Corporation 8979 0.09
Tower Research Capital LLC (TRC) 5844 0.06



Head Job title Payment Year of birth
Dr. Sam Lee Ph.D. Co-Founder, Co-CEO & President 559.82k 1960 (65 years)
Prof. Roger D. Kornberg Ph.D. Co-Founder, Independent Chairman, Chief Scientist & Chairman of Scientific Advisory Board 1947 (78 years)
Mr. James J. Martin CPA, M.B.A. Co-CEO, CFO & Corporate Secretary 1967 (58 years)

Address: United States, Bothell. WA, 19805 North Creek Parkway - open in Google maps, open in Yandex maps
Website: https://www.cocrystalpharma.com